Investors

Corporate Profile
We are a clinical-stage biopharmaceutical company developing innovative therapies for rare forms of cancer and orphan diseases.

Leveraging our proprietary ERYCAPS platform, which uses a novel technology to encapsulate therapeutic drug substances inside erythrocytes, or red blood cells, we have developed a pipeline of product candidates targeting markets with high unmet medical needs. Our initial focus is on the treatment of blood cancers, including acute lymphoblastic leukemia, or ALL, and acute myeloid leukemia, or AML, by depriving tumors of nutrients necessary for their survival, which is referred to as tumor starvation.
Stock Quote
ERYP.PA (Common Stock)
ExchangeParis (Euro)
Price€18.82
Change (%) Stock is Up 0.02 (0.11%)
Volume13,570
Data as of 09/23/16 5:35 p.m. ET
Refresh quote
Recent NewsMore >>
DateTitle  
06-Sep-2016ERYTECH Reports Business and Financial Update for the First Half of 2016
Conference call and webcast scheduled for Wednesday, September 7th at 3:00 pm CET/9:00 am EDT Ongoing review by European Medicines Agency (EMA) of Marketing Authorization Application (MAA) for GRASPA for the treatment of acute lymphoblastic leukemia (ALL) Completed patient enrollment in Phase 2b study of eryaspase (GRASPA®) for the treatment of acute myeloid leukemia (AML) Enrollment of p... 
 Printer Friendly Version
05-Sep-2016ERYTECH Appoints Allene M. Diaz to its Board of Directors
LYON, France--(BUSINESS WIRE)--Sep. 5, 2016-- Regulatory News: ERYTECH Pharma (Euronext Paris:ERYP) (Paris:ERYP) (ADR:EYRYY), a French biopharmaceutical company developing ‘tumor starvation’ treatments for acute leukemia and other oncology indications with unmet medical needs, today announced the appointment of Allene M. Diaz to its Board of Directors as a nonvoting member (censeur). As censeur, Ms. Diaz will initially attend all Board of ... 
 Printer Friendly Version
01-Sep-2016Erytech : Information Related to Total Number of Voting Rights and Shares Composing the Share Capital - August 2016
Article 223-16 of general regulation of French Autorité des Marchés Financiers LYON, France--(BUSINESS WIRE)--Sep. 1, 2016-- Regulatory News: Erytech (Paris:ERYP) (ADR:EYRYY): Date   Total of shares composing the share capital   Total of brut(1) voting ri... 
 Printer Friendly Version
30-Aug-2016ERYTECH to Hold Q2 2016 Business Update Conference Call on September 7th, 2016
LYON, France--(BUSINESS WIRE)--Aug. 30, 2016-- Regulatory News: ERYTECH (Euronext Paris: FR0011471135 - ERYP) (Paris:ERYP) (ADR:EYRYY), a French biopharmaceutical company developing innovative ‘tumor starvation’ treatments for acute leukemia and other oncology indications with unmet medical needs, today announced that it will release its financial results and business update for the quarter ended June 30, 2016 on Tuesday, September 06, 2... 
 Printer Friendly Version
Upcoming EventsMore >>
DateTitle
11/03/16
Third Quarter 2016 Financial Results and Business Update: press release on Thursday, November 3, 2016, (after market)
11/04/16 3:00 p.m. CET
Third Quarter 2016 Financial Results and Business Update: Conference Call
Receive E-mail Alerts
Sign up to receive e-mail alerts whenever Erytech Pharma SA posts new information to the site. Just enter your e-mail address and click Submit.
 
Data provided by Nasdaq. Minimum 15 minutes delayed. View Attributions and Sources
Top